Moleculin Biotech ups ATM offering cap to $19.7M after selling $1.89M of stock

Filed August 21, 2026 · ~1 min read

Key Changes

• high

  Moleculin increased the maximum gross sales price under its at-the-market (ATM) offering to $19.7 million, up from prior caps of up to $6.5 million and $8.2 million.

  The Offering view on EDGAR →
• high

  The company has already sold 486,775 shares under the ATM for gross proceeds of about $1.89 million, indicating ongoing dilution.

  The Offering view on EDGAR →
• medium

  The last reported sale price on Nasdaq was $0.5906 per share on August 20, 2026, below the $1.00 threshold that can trigger Nasdaq delisting concerns.

  The Offering view on EDGAR →